title: Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up.
authors.forename: J L
authors.initials: JL
authors.lastname: Houeto
authors.forename: V
authors.initials: V
authors.lastname: Mesnage
authors.forename: M L
authors.initials: ML
authors.lastname: Welter
authors.forename: L
authors.initials: L
authors.lastname: Mallet
authors.forename: Y
authors.initials: Y
authors.lastname: Agid
authors.forename: B P
authors.initials: BP
authors.lastname: Bejjani
mesh_terms: D003221:Confusion / Q000209:etiology; D003863:Depression / Q000139:chemically induced; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D004599:Electric Stimulation Therapy; D005500:Follow-Up Studies; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D019964:Mood Disorders / Q000209:etiology; D009459:Neuroleptic Malignant Syndrome / Q000517:prevention & control; D010300:Parkinson Disease / Q000628:therapy*; D011788:Quality of Life; D012920:Social Behavior Disorders / Q000139:chemically induced; D013375:Substance Withdrawal Syndrome / Q000209:etiology; D020531:Subthalamic Nucleus / Q000502:physiology; D013995:Time; D016896:Treatment Outcome
chemical_list: D018491:Dopamine Agonists; D007980:Levodopa